🔴 Gossamer Bio is trading 5.4% down — no clear company announcement explains the drop

Gossamer Bio is trading at $10.13, down 5.37%, with no reported company announcement explaining the October 5 decline.

• An October 1 report noted divided analyst views; Piper Sandler cut its target to US$4 from US$15, citing Phase 3 PROSERA concerns and implications for the PAH filing.
• That view is context, not a confirmed cause of the October 5 move.
• Markets were mixed: S&P 500 up 0.09%, Nasdaq up 0.58%, Dow down 0.58%; no broad-market direction clearly explains the drop.